this is interesting... it is actually NovaQuest affiliated company Quintiles that is responsible for the market access strategy, pricing and product management from Bronchitol in EU. so if they are unhappy then they should not be shaking a finger at PXS- there is more to the communication that we are presently aware of IMO. see links below:
http://www.businesswire.com/news/ho...mprehensive-Commercial-Solutions#.U7dX8HyKDmQ
http://www.novaquest.com/novaquest-raises-u-s-459-million-pharma-opportunities-fund-iii/
Let's take a positive view for a second, page-2
-
- There are more pages in this discussion • 19 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add SNT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
3.3¢ |
Change
-0.001(2.94%) |
Mkt cap ! $39.40M | |||
| Open | High | Low | Value | Volume |
| 3.4¢ | 3.4¢ | 3.2¢ | $42.79K | 1.268M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 186858 | 3.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 3.4¢ | 252947 | 5 |
View Market Depth
| Last trade - 15.29pm 02/08/2024 (20 minute delay) ? |
| SNT (ASX) Chart |